RR-11a
Based on 4 publication(s) in Google Scholar
RR-11a is a synthetic enzyme inhibitor of Legumain (IC50=31-55 nM). RR-11a can be used for the research of cancer and acute myocardial infarction (AMI).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 96.20%
- CAS No.: 1361390-56-8
- Formule: C24H28N6O10
- Masse moléculaire:560.51
-
Stockage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Neuronal Signaling Compound Library
HY-L013
-
Covalent Screening Library
HY-L036
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) RR-11a
More
Activité biologique
|
Legumain 31-55 nM (IC50) |
Legumain-targeted RR-11a-coupled nanoparticles reveal high ligand-receptor affinity, enhance solid-tumor penetration and uptake by tumor cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
RR-11a (20 mg/kg; daily i.p. for 30 days) improves cardiac function, decreases cardiac rupture rate, and attenuates left chamber dilation and wall thinning post-AMI in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1361390-56-8
-
Appearance Solid
-
Masse moléculaire 560.51
-
Formule C24H28N6O10
-
Color White to off-white
-
SMILES
O=C(N[C@@H](C)C(N[C@@H](C)C(NN(CC(N)=O)C(/C=C/C(ON1C(CCC1=O)=O)=O)=O)=O)=O)OCC2=CC=CC=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Dis
Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. [Abstract]2020 Nov 26;11(11):1014. PMID: 33243972 -
J Med Chem
Legumain-Cleavable Top1i Antibody-Drug Conjugates without Self-Immolative Spacers Demonstrate Potent Antitumor Activity. [Abstract]2025 Dec 11;68(23):25505-25522. PMID: 41267393 -
J Mol Med
Legumain promotes fibrogenesis in chronic pancreatitis via activation of transforming growth factor β1. [Abstract]2020 Jun;98(6):863-874. PMID: 32415356 -
J Cell Commun Signal
P2X7 receptors promote atrial remodeling and atrial fibrillation susceptibility via reactive oxygen species-mediated mitogen-activated protein kinase signaling activation. [Abstract]2026 Apr 30:20:e70071. PMID: 42078487
Solvant et solubilité
DMSO : 100 mg/mL (178.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.46 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Mice[1]
Mice bearing 4T1 orthothopic tumors of approximately 500 mm3 are injected once intravenously with RR-11a+ or RR-11a-nanoparticles labeled with rhodamine B. Alternatively, mice are injected intravenously 3 times at 48-hour intervals with RDZ-218, NP-DOX, free DOX, or saline. Twenty-four hours after the final treatment, animals are sacrificed and spleen, kidney, lungs, liver, heart and tumor are collected, frozen in OCT compound, immediately sectioned and imaged by fluorescence microscopy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Liao D, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomedicine. 2011 Dec;7(6):665-73. [Content Brief]
[2]. Ralph A, et al. Nanoparticle-based tumor-targeted drug delivery. Patent: CA2809617C
[3]. Yang H, et al. Legumain is a predictor of all-cause mortality and potential therapeutic target in acute myocardial infarction. Cell Death Dis. 2020;11(11):1014. Published 2020 Nov 26. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7841 mL | 8.9204 mL | 17.8409 mL | 44.6022 mL |
| 5 mM | 0.3568 mL | 1.7841 mL | 3.5682 mL | 8.9204 mL | |
| 10 mM | 0.1784 mL | 0.8920 mL | 1.7841 mL | 4.4602 mL | |
| 15 mM | 0.1189 mL | 0.5947 mL | 1.1894 mL | 2.9735 mL | |
| 20 mM | 0.0892 mL | 0.4460 mL | 0.8920 mL | 2.2301 mL | |
| 25 mM | 0.0714 mL | 0.3568 mL | 0.7136 mL | 1.7841 mL | |
| 30 mM | 0.0595 mL | 0.2973 mL | 0.5947 mL | 1.4867 mL | |
| 40 mM | 0.0446 mL | 0.2230 mL | 0.4460 mL | 1.1151 mL | |
| 50 mM | 0.0357 mL | 0.1784 mL | 0.3568 mL | 0.8920 mL | |
| 60 mM | 0.0297 mL | 0.1487 mL | 0.2973 mL | 0.7434 mL | |
| 80 mM | 0.0223 mL | 0.1115 mL | 0.2230 mL | 0.5575 mL | |
| 100 mM | 0.0178 mL | 0.0892 mL | 0.1784 mL | 0.4460 mL |
RR-11a Related Classifications
HY-112205 Related Classifications
Powered by Bioz